Last 48 quarters of trend data · Healthcare · Medical - Diagnostics & Research
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -63.57 | — | — | 33.76 | 35.38 | 77.78 | — | 37.28 | 29.68 | 52.11 | 16.33 | 28.99 | 27.81 |
| — | — | — | -9.4% | +19.2% | +49.3% | — | +28.6% | +6.7% | +107.6% | +9.4% | +16.3% | +4.7% | |
| P/S Ratio | 2.22 | 1.96 | 2.52 | 1.83 | 1.79 | 2.01 | 2.35 | 2.53 | 2.61 | 3.47 | 3.01 | 2.46 | 2.55 |
| — | -2.7% | +7.1% | -27.9% | -31.3% | -42.1% | -21.8% | +2.8% | +2.2% | +37.7% | +18.3% | +1.3% | -14.4% | |
| P/B Ratio | 2.86 | 2.61 | 3.12 | 2.13 | 2.18 | 2.44 | 2.69 | 2.67 | 2.84 | 3.79 | 3.34 | 3.02 | 3.28 |
| — | +6.8% | +16.0% | -20.4% | -23.3% | -35.7% | -19.3% | -11.5% | -13.4% | +15.3% | -9.9% | -16.1% | -23.9% | |
| P/FCF | 17.19 | — | 42.78 | 10.30 | 10.92 | 17.60 | 28.18 | 12.00 | 17.38 | 69.20 | 21.39 | 18.12 | 33.51 |
| — | — | +51.8% | -14.2% | -37.2% | -74.6% | +31.7% | -33.8% | -48.1% | -93.3% | +11.4% | -54.5% | -23.1% | |
| EV / EBITDA | 12.91 | 14.24 | 16.22 | 11.15 | 11.38 | 13.67 | — | 15.54 | 14.06 | 19.87 | 17.56 | 13.96 | 14.12 |
| — | +4.2% | — | -28.2% | -19.0% | -31.2% | — | +11.3% | -0.4% | +46.0% | +20.6% | -1.4% | +0.6% | |
| EV / EBIT | 23.16 | 22.22 | 26.77 | 21.68 | 24.66 | 41.76 | — | 26.29 | 21.93 | 31.34 | 15.47 | 21.93 | 20.92 |
| — | -46.8% | — | -17.5% | +12.5% | +33.3% | — | +19.9% | +4.8% | +55.4% | +23.1% | -7.7% | -16.5% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Charles River Laboratories International, Inc.'s operating margin was 12.0% in Q1 2026, down 0.1 pp QoQ and up 4.5 pp YoY. Gross margin contracted 13.1% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 30.5% | 28.0% | 31.0% | 33.7% | 34.6% | 32.3% | 28.4% | 34.6% | 34.5% | 34.1% | 35.9% | 35.2% | 37.6% |
| — | -13.1% | +9.2% | -2.5% | +0.4% | -5.3% | -21.1% | -1.9% | -8.4% | -7.1% | -0.9% | -5.8% | +2.7% | |
| Operating Margin | 12.6% | 12.0% | 12.1% | 13.3% | 9.7% | 7.6% | -16.7% | 11.6% | 14.8% | 12.5% | 13.1% | 14.8% | 15.6% |
| — | +58.7% | +172.3% | +14.5% | -34.4% | -39.1% | -227.5% | -21.2% | -5.0% | -23.6% | -11.9% | -3.3% | -19.2% | |
| Net Margin | -3.6% | -1.5% | -27.8% | 5.4% | 5.1% | 2.6% | -21.5% | 6.8% | 8.8% | 6.7% | 18.5% | 8.5% | 9.2% |
| — | -157.6% | -29.3% | -20.4% | -42.2% | -61.1% | -216.6% | -20.1% | -4.2% | -33.6% | +8.3% | -12.7% | -18.5% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -4.3% | -0.5% | -8.3% | 1.6% | 1.6% | 0.8% | -5.9% | 1.8% | 2.4% | 1.8% | 5.3% | 2.6% | 3.0% |
| — | -163.4% | -41.2% | -12.1% | -34.5% | -58.7% | -210.2% | -31.2% | -19.9% | -45.2% | -18.9% | -26.9% | -26.3% | |
| ROA | -2.0% | -0.2% | -3.8% | 0.7% | 0.7% | 0.3% | -2.8% | 0.9% | 1.1% | 0.8% | 2.4% | 1.1% | 1.3% |
| — | -159.2% | -35.9% | -16.2% | -38.2% | -59.1% | -217.3% | -24.2% | -10.9% | -38.9% | -5.3% | -12.2% | -16.2% | |
| ROIC | 6.3% | 1.5% | 1.5% | 1.7% | 1.3% | 0.9% | -2.0% | 1.4% | 1.8% | 1.5% | 1.6% | 1.9% | 2.0% |
| — | +62.2% | +174.6% | +22.9% | -29.1% | -36.5% | -227.5% | -25.7% | -12.3% | -30.2% | -24.2% | -4.1% | -19.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Charles River Laboratories International, Inc.'s Debt/EBITDA ratio is 16.3x, up from 15.4x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 5.0% YoY to 1.36x, tightening the short-term liquidity position. Debt/Equity has risen for 3 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.95 | 1.02 | 0.95 | 0.76 | 0.82 | 0.92 | 0.78 | 0.72 | 0.75 | 0.83 | 0.84 | 0.87 | 0.93 |
| — | +11.0% | +22.9% | +5.8% | +9.0% | +10.8% | -7.3% | -16.8% | -19.4% | -17.0% | -18.2% | -30.9% | -26.4% | |
| Debt / EBITDA | 3.36 | 16.34 | 15.44 | 12.02 | 12.68 | 15.31 | — | 13.42 | 11.94 | 14.57 | 14.37 | 12.61 | 12.70 |
| — | +6.7% | — | -10.5% | +6.3% | +5.1% | — | +6.4% | -6.0% | +12.9% | +12.0% | -15.2% | -1.9% | |
| Current Ratio | 1.29 | 1.36 | 1.29 | 1.37 | 1.36 | 1.43 | 1.41 | 1.48 | 1.58 | 1.75 | 1.52 | 1.45 | 1.49 |
| — | -5.0% | -8.5% | -7.5% | -14.0% | -18.0% | -7.4% | +1.6% | +6.0% | +18.4% | +15.7% | +4.1% | +12.4% | |
| Quick Ratio | 1.02 | 1.03 | 1.02 | 1.10 | 1.10 | 1.16 | 1.13 | 1.14 | 1.21 | 1.37 | 1.16 | 1.16 | 1.21 |
| — | -10.8% | -9.4% | -4.2% | -9.2% | -15.5% | -2.8% | -1.2% | +0.3% | +13.3% | +7.4% | +1.8% | +11.6% | |
| Interest Coverage | 4.74 | 4.48 | 5.06 | 4.43 | 3.38 | 2.29 | -6.68 | 4.01 | 4.65 | 3.83 | 7.22 | 4.35 | 4.67 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CRL stock.
Charles River Laboratories International, Inc.'s current P/E is -63.6x. The average P/E over the last 2 quarters is 34.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Charles River Laboratories International, Inc.'s current operating margin is 12.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Charles River Laboratories International, Inc.'s business trajectory between earnings reports.